David Scholl Elected To Chairman Of Omeris' Board Of Trustees
Columbus, Ohio | December 21, 2004 -- Omeris announced the election of David Scholl, PhD, to chairman of its Board of Trustees. He is president and CEO of Athens, Ohio-based Diagnostic Hybrids, which develops and manufactures diagnostic cell cultures and virus detection kit systems used in the clinical diagnosis of infectious and autoimmune diseases, Dr. Scholl has been an Omeris Board member since 2002.
The Omeris Board of Trustees also includes: John Bantle, II, PhD, Ohio University; Timothy Biro, Ohio Innovation Fund; Mark Collar, Procter & Gamble Pharmaceuticals; Tony Dennis, PhD, Omeris; Joseph Hahn, MD, The Cleveland Clinic Foundation; Jane Henney, MD, senior vice president and provost for health affairs at the University of Cincinnati; Mike Hooven, chairman and CTO of AtriCure; Peter Kleinhenz, CID Equity Partners; John Rice, PhD, Triathlon Medical Ventures; Richard Rosen, Battelle; Fred Sanfilippo, MD, PhD, The Ohio State University; Bill Sanford, SYMARK; Jim Scozzie, PhD, BioEnterprise; and Donald Wetherhold, RxPedite.
Omeris is a nonprofit organization supported by the Thomas Edison Program of the Ohio Department of Development. Its mission is to accelerate bioscience discovery, innovation and commercialization of global value, driving economic growth, and improving quality of life in Ohio. Omeris is headquartered in Columbus, with regional business development affiliates in Cleveland, Columbus, Cincinnati and Athens.
